You are here » Home » Companies » Company Overview » Ankur Drugs & Pharma Ltd

Ankur Drugs & Pharma Ltd.

BSE: 531683 Sector: Health care
NSE: ANKURDRUGS ISIN Code: INE238D01012
BSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
NSE LIVE 00:00 | 10 Sep Stock Is Not Traded.
OPEN
PREVIOUS CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr)
Buy Price
Buy Qty
Sell Price
Sell Qty
OPEN
CLOSE
VOLUME
52-Week high 0.00
52-Week low 0.00
P/E
Mkt Cap.(Rs cr)
Buy Price
Buy Qty
Sell Price
Sell Qty

Ankur Drugs & Pharma Ltd. (ANKURDRUGS) - Chairman Speech

Company chairman speech

ANKUR DRUGS AND PHARMA LIMITED ANNUAL REPORT 2010-2011 CHAIRMAN'S REPORT Dear Shareowners, 'The joy of visualizing a bright future is not without challenges' The year gone by was indeed full of challenges. Challenges from all sides in a heap, Challenge to complete the expansion project within the regulatory time deadline; challenge to fund the project; challenge of execution ; challenge of co-ordinating several/various activities for survival, streamlining and growth. Your Company had to restrategise its planned activities in tune with demands of time, money, efforts and manpower to complete and start the project to avail the various tax benefits available at Baddi. And I have great satisfaction to state that indeed we have met the deadline. We have consciously taken a big hit on the profits by way of increased depreciation and interest outflow. In view of the above circumstances the board has not been able to declare dividends. The entire gamut of exercise was undertaken because we visualize a bright future for the company. Short term aberrations do not deter the ambitious. We take it as a challenge to overcome them and become victorious. We are on our path towards it and once again very bright future lies ahead of us. Our future focus is to scale up our activites taking advantage of the knowledge, the experience, dedicated manpower and infrastructure that we have built and established. The management strongly believes that 'BEING COMMITTED, NOTHING IS DIFFICULT'. The newly set up production facilities at Baddi have been validated by major leading international pharma companies. The Company has large numbers of orders in hand, which is lined up to be executed during the year. The CDR EG has approved the restructuring package of the Company and constraints of working capital have been addressed to a large extent to regain growth momentum. Ankur today is one of the leading company in the area of Contract Manufacturing of pharmaceutical formulations of various dosage forms to leading national and multinational pharma companies. For the current year 2011-12, the monsoon is better in major parts of India, but the monstrous rising inflation is expected to cast a dark cloud on the horizon of growth. Before I conclude, let me assure you of our commitment to create value for our stakeholders. I take this opportunity to thank the board for their constant guidance and support and Ankur employees for their commitment and contribution. We value the confidence that you have reposed in Ankur and sincerely look forward to your continued support and encouragement. Warm regards, Purnandu Jain Chairman and Managing Director Saturday, September 03, 2011.

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard